Our seamless 3-phase process ensures viable medical technology is sourced thoughtfully, developed fully, and exited properly.

Phase I: SOURCE

Through close relationships with inventors, leaders in academia, government, and the private sector, we identify cutting-edge MedTech innovations with the power to revolutionize patient care and outcomes.

We carefully review their portfolios of IP and select only the products we believe have true feasibility, strong technological advantages, financial viability, and the ability to change the lives of patients and clinicians. We pass on about 95% of technologies early and often if they don't meet our strict criteria for viability in the market. But we also provide feedback so that inventors can rework products that have potential.

Phase II: BUILD

We form an OpCo around the approved technology to further develop the technological innovation roadmap and complete R&D up to Investigational Device Exemption (IDE).

Because we own the ecosystem, control all the variables, know the game plan up front, and sit on the boards of the Operating Companies, once we bring a technology onboard, we accelerate its growth, building it out more quickly and efficiently than traditional VC companies.

We also work both directions, not only finding new technologies and presenting them to potential end users, but also speaking with medical personnel and manufacturers about gaps they’d like to close and then returning to Phase 1 to source the solutions they’ve told us they need.

Phase III: SELL

Once the technology has been fully developed, we find the right strategic/exit partners who can effectively scale and commercialize the technological advancements, ensuring they reach their ultimate audience—patients and clinicians.